Clearside Biomedical

Clearside Biomedical Accounts Payable

Delisted

The Accounts Payable of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 1.45 M USD. In the previous year, Accounts Payable was 2.21 M USD — a change of -34.15% (lower).

Accounts Payable

1.45 MUSD

YoY

-34.15%

Last updated:

Accounts Payable of Clearside Biomedical is 2024 1.45 M USD. Accounts Payable of Clearside Biomedical was 2023 2.21 M USD. It decreases by -34.15% lower compared to the previous year.

The Clearside Biomedical Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2017
5.38 M USD
Jan 1, 2018
6.87 M USD
Jan 1, 2019
1.28 M USD
Jan 1, 2020
2.00 M USD
Jan 1, 2021
940,000.00 USD
Jan 1, 2022
1.05 M USD
Jan 1, 2023
2.21 M USD
Jan 1, 2024
1.45 M USD
The Clearside Biomedical Accounts Payable history
YEARAccounts PayableYoY
1.45 MUSD-34.15%
2.21 MUSD+110.00%
1.05 MUSD+11.70%
940,000.00USD-53.00%
2.00 MUSD+56.25%
1.28 MUSD-81.37%
6.87 MUSD+27.70%
5.38 MUSD+107.72%
2.59 MUSD+76.19%
1.47 MUSD+16.67%
1.26 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Accounts Payable of Clearside Biomedical is 1.45 M USD in 2024.

Accounts Payable of Clearside Biomedical changed from 2.21 M USD to 1.45 M USD, representing a -34.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clearside Biomedical

All Key Metrics — Clearside Biomedical